1 week Ago By Defense World Staff
Corebridge Financial Inc. trimmed its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 7.
0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,860 shares of the company’s stock after selling 972 shares during the period. Corebridge Financial Inc.
’s holdings in Castle Biosciences were worth $343,000 at the end of the most recent quarter. Several other large investors have also recently added to or reduced their stakes in the company. Perkins Capital Management Inc.
increased its position in shares of Castle Biosciences by 4.7% during the fourth quarter. Perkins Capital Management Inc.
now owns 34,165 shares of the company’s stock valued at $910,000 after purchasing an additional 1,525 shares during the period. Vanguard Group Inc. boosted its stake in Castle Biosciences by 4.
8% during the fourth quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company’s stock worth $48,837,000 after buying an additional 83,783 shares in the last quarter.
Fox Run Management L.L.C.
bought a new stake in Castle Biosciences in the 4th quarter valued at $286,000. KLP Kapitalforvaltning AS bought a new stake in Castle Biosciences in the 4th quarter valued at $128,000. Finally, Sei Investments Co.
raised its stake in shares of Castle Biosciences by 9.6% in the 4th quarter. Sei Investments Co.
now owns 41,491 shares of the company’s stock valued at $1,106,000 after buying an additional 3,617 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.
Castle Biosciences Price PerformanceShares of Castle Biosciences stock opened at $19.30 on Friday. The stock has a market capitalization of $556.
59 million, a price-to-earnings ratio of 96.50 and a beta of 1.11.
The firm’s 50-day moving average price is $22.51 and its two-hundred day moving average price is $27.16.
The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.
02. Castle Biosciences, Inc. has a 1-year low of $16.
97 and a 1-year high of $35.84. Analyst Ratings ChangesSeveral analysts have recently weighed in on CSTL shares.
Stephens reiterated an “overweight” rating and set a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Guggenheim set a $30.
00 price objective on Castle Biosciences and gave the company a “buy” rating in a report on Friday, March 28th. Finally, Robert W. Baird upped their price objective on Castle Biosciences from $36.
00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $38.
75.Read Our Latest Analysis on Castle BiosciencesInsider Transactions at Castle BiosciencesIn other news, Director Daniel Bradbury sold 7,867 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $28.
17, for a total value of $221,613.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Also, insider Derek J. Maetzold sold 2,130 shares of Castle Biosciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $19.
52, for a total value of $41,577.60. Following the completion of the transaction, the insider now directly owns 78,335 shares of the company’s stock, valued at $1,529,099.
20. This represents a 2.65 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. Insiders have sold 35,071 shares of company stock valued at $775,682 in the last three months. 7.
20% of the stock is owned by corporate insiders. About Castle Biosciences (Free Report)Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured StoriesFive stocks we like better than Castle BiosciencesHow to Most Effectively Use the MarketBeat Earnings ScreenerJoby Aviation: Operational Momentum vs. Market SentimentFinancial Services Stocks InvestingBroadcom’s Big Outperformance Shows Strength Amid Tariff Decline3 REITs to Buy and Hold for the Long TermCarvana: Can Turnaround Strength Outdrive Market Headwinds?Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc.
(NASDAQ:CSTL – Free Report)..
